PURPOSE: A bisphosphonate compound is provided to suppress bond of PTP-1B(Protein Tyrosine Phosphate 1B) and IR(Insulin Receptor), to treat insulin secretion in pancreatic islet, and to be used as a preventive and therapeutic agent for type 2 diabetes. CONSTITUTION: A pharmaceutical composition for preventing or treating diabetes contains zoledronate or a pharmaceutically acceptable salt thereof as an active ingredient. The diabetes is type 2 diabetes. Zoledronate or a pharmaceutically acceptable salt is administered to an individual in an amount of 0.001-0.2 mg/day, 0.15 mg/day, or 0.1 mg/day to prevent or treat diabetes. Zoledronate or a pharmaceutically acceptable salt is used by oral, intravenous, subcutaneous, and intrarectal administration. Zoledronate or a pharmaceutically acceptable salt suppresses bond of PTP-1B with IR. [Reference numerals] (AA,FF) Insulin acceptor

暂无附图